SynCardia Total Artificial Heart Powers First UCSF Heart Transplant After Five Implants
UCSF Health performed its first heart transplant after supporting a 37-year-old Central Valley patient with end-stage heart failure using Picard Medical’s SynCardia Total Artificial Heart, marking the fifth SynCardia implant at California’s top transplant center. Three months post-implant, the patient received a donor heart and is recovering well before returning home.
1. Clinical Milestone at UCSF
In August 2025, UCSF Health implanted its fifth SynCardia Total Artificial Heart in a 37-year-old patient with end-stage heart failure. Following a six-hour surgery at the Helen Diller Medical Center at Parnassus Heights, the patient was discharged on support and underwent a successful donor heart transplant three months later, showing strong recovery.
2. Device Technology and Approvals
Picard Medical’s SynCardia Total Artificial Heart is the only FDA- and Health Canada-approved commercial artificial heart, with over 2,100 implants across 27 countries. The device fully replaces biventricular function and stabilizes patients until a donor heart becomes available, while Picard advances its next-generation Emperor TAH for fully implantable long-term support.
3. Market Impact and Outlook
This successful bridge-to-transplant case at a top-ranked transplant center underscores growing clinical adoption of SynCardia technology at leading hospitals. The milestone could bolster Picard Medical’s credibility, support wider insurance coverage discussions and accelerate uptake ahead of its future product launches.